Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Exploratory Study of Nivolumab With or Without Ipilimumab According to the Percentage of Tumoral CD8 Cells in Participants With Advanced Metastatic Cancer

NCT03651271 is registered in ClinicalTrials.gov with Parker Institute for Cancer Immunotherapy as lead sponsor.

NCT NCT03651271
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03651271 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Exploratory Study of Nivolumab With or Without Ipilimumab According to the Percentage of Tumoral CD8 Cells in Participants With Advanced Metastatic Cancer
Lead sponsor
Parker Institute for Cancer Immunotherapy
Phase
Phase 2
Overall status
Completed
Start date
October 17, 2018
Completion date
June 30, 2023
Enrollment
100 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

advanced metastatic cancer, advanced prostate cancer